Retina Clinic: Current Treatment Options in nAMD

Retina Clinic: Current Treatment Options in DME

Retina Clinic: Current Treatment Options in DME
RestartResume

Our experts clarify how to adopt the most recent advances into practice so you can achieve durable results for your patients with DME.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Several novel treatment options are now available for DME, but do you know how which patients to treat with these agents to prolong durability and improve access? Join Dr. David Eichenbaum and Dr. Mark Barakat as they discuss patient management approaches based on the latest clinical data.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    David Eichenbaum, MD

    Director of Research
    Retina Vitreous Associates
    St. Petersburg, FL

    Commercial Interest Speakers Bureau: Allergan, Apellis, Bausch & Lomb, Bayer, DORC, EyePoint Pharmaceuticals, Inc., Genentech, Novartis
    Consulting Fees: Alimera, Allergan, Apellis, Bausch & Lomb, Coherus, Crinetics, DORC, EyePoint Pharmaceuticals, Inc., Genentech, Gyroscope, Iveric Bio, KKR, Kodiak, Novartis, Opthea, RecensMedical, Regeneron, REGENXBIO, US Retina, Vial
    Contracted Research: 4DMT, Alkahest, Annexon, AsclepiX, Bayer, Chengdu, EyePoint Pharmaceuticals, Inc., Gemini, Genentech, Gyroscope, Ionis, Iveric Bio, Kodiak Sciences, Mylan, NGM, Novartis, Ocular Therapeutix, Opthea, RecensMedical, Regeneron, REGENXBIO, Unity
    Equity/Stockholder: Boston Image Reading Center, Clearside, Hemera Biopharmaceuticals, Network Eye, Outlook, US Retina
    Founder: Network Eye

    Faculty:
    Mark R. Barakat, MD
    Director of Retinal Research Institute
    Retinal Consultants of Arizona
    Clinical Assistant Prof of Ophthalmology
    Univ of Arizona College of Med - Phoenix
    Phoenix, AZ

    Consulting Fees: AbbVie, Adverum, Alcon, Allegro, Allergan, Alimera, Apellis, Biogen, Bausch & Lomb, Clearside, Coherus BioSciences, EyePoint Pharmaceuticals, Inc., Kodiak Sciences, Genentech, Graybug Vision, Inc., Novartis, Ocular Therapeutix, Opthea, Outlook, Palatin, Regeneron, REGENXBIO, RevOpsis Therapeutics
    Contracted Research: Adverum, Annexon, Clearside, EyePoint, Gemini, Genentech, Graybug Vision, Inc., Gyroscope, Kodiak Sciences, Novartis, Oculis Therapeutics, Opthea, Oxular, Oxurion, Regeneron, REGENXBIO, Ribomic, Stealth, Unity
    Ownership Interest: NeuBase, Oxurion, RevOpsis Therapeutics

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Stephanie Wenick, MPhil, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify patients with diabetic macular edema who would benefit from novel durable treatment options
  • Target Audience

    This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and optometrists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Global Learning Collaborative is accredited by COPE to provide continuing education to optometrists.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the  credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    This course is COPE approved for <insert number> hours of CE credit. Course ID is 64691-PS. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free